Introduction {#S1}
============

Tertiary lymphoid structures (TLS) are transient ectopic lymphoid organizations that develop after birth in non-lymphoid tissues, in situations of chronic inflammation. They display an overall organization similar to that observed in canonical secondary lymphoid organs (SLOs), such as lymph nodes (LNs), with a T cell-rich area characterized by a T cell and mature DC-Lamp^+^ dendritic cell (DCs) cluster, a B-cell-rich area composed of a mantle of naïve B cells surrounding an active germinal center (GC) ([@B1]--[@B3]), the presence of high endothelial venules (HEVs), a particular type of blood vessels expressing peripheral node addressins (PNAd) and specialized in the extravasation of circulating immune cells, and the secretion of chemokines (CCL19, CCL21, CXCL10, CXCL12, and CXCL13) that are crucial for lymphocyte recruitment and entry into the LN ([@B4]--[@B8]). TLS have been detected in the tumor invasive margin and/or in the stroma of most cancers and their densities correlate with a favorable clinical outcome for the patients (Table [1](#T1){ref-type="table"}). A series of studies performed by our group in non-small-cell lung cancer (NSCLC) demonstrated that TLS are important sites for the initiation and/or maintenance of the local and systemic T- and B-cell responses against tumors, in accordance with a specific signature of genes related to T and B cell lineage, chemotaxis, Th1 polarization, lymphocyte activation, and effector function associated with TLS presence (Table [2](#T2){ref-type="table"}). They represent a privileged area for the recruitment of lymphocytes into tumors and the generation of central-memory T and B cells that circulate and limit cancer progression ([@B5], [@B9], [@B10]).

###### 

**Prognostic value of TLS in primary and metastatic tumors**.

  Criteria                             Cancer type                 Stages of the disease   No. of patients               TLS detection IHC    TLS detection gene expression   Prognostic value   Reference
  ------------------------------------ --------------------------- ----------------------- ----------------------------- -------------------- ------------------------------- ------------------ -----------
  Primary tumors                       Breast carcinoma            I--III                  146                           PNAd                 --                              Positive           ([@B8])
  I--III                               146                         DC-Lamp                 --                            Positive             ([@B11])                                           
  I--III                               794                         --                      T~FH~, CXCL13                 Positive             ([@B12])                                           
  Breast carcinoma (triple negative)   I--III                      769                     H&S                           --                   Positive                        ([@B13])           
  Colorectal cancer                    I--IV                       350                     H&S                           --                   Positive                        ([@B14])           
  ND                                   25                          DC-Lamp                 --                            Positive             ([@B15])                                           
  I--IV                                40                          CD3, CD83               --                            Positive             ([@B16])                                           
  II                                   185                         CD3                     --                            Positive             ([@B17])                                           
  III                                  166                         CD3                     --                            No value             ([@B17])                                           
  0--IV-A                              21                          --                      12-chemokine genes            Positive             ([@B3])                                            
  I--IV                                125                         --                      CXCL13 and CD20               Positive             ([@B18])                                           
  Gastric cancer                       All without chemo           82                      CD20                          --                   Positive                        ([@B19])           
  I--III                               365                         --                      both Th1 and B                Positive             ([@B19])                                           
  NSCLC                                I--II                       74                      DC-Lamp                       --                   Positive                        ([@B1])            
  I--IV                                362                         DC-Lamp                 --                            Positive             ([@B9])                                            
  III with neo-adj. chemo              122                         DC-Lamp, CD20           --                            Positive             ([@B2])                                            
  Melanoma                             I-A--III-A                  82                      DC-Lamp                       --                   Positive                        ([@B20])           
  IV                                   21                          --                      12-chemokine genes            Positive             ([@B21])                                           
  Oral SCC                             All                         80                      CD3, CD20, CD21, BCL6, PNAd   --                   Positive                        ([@B22])           
  Pancreatic cancer                    All                         308 + 226               H&E                           --                   Positive                        ([@B23])           
  RCC                                  All                         135                     DC-Lamp                       --                   Positive                        ([@B24])           
  Hepatocellular Cancer                All                         82                      H&S                           11-chemokine genes   Negative                        ([@B25])           
  Biliary tract cancer                 All                         335                     CD20 (TMA)                    --                   No value                        ([@B26])           
  Metastatic tumors                    Colorectal cancer (liver)   All                     14 + 51                       CD20                 --                              Positive           ([@B27])
  Colorectal cancer (lung)             ND                          140                     DC-Lamp                       --                   Positive                        ([@B15])           

###### 

**Expression of genes associated with TLS presence in human cancers**.

  Name of the gene   Main names of the protein                              Main immune functions and process                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Cluster of gene related to TLS presence                      Reference
  ------------------ ------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------ ----------------------------------------
  CCL2               CCL2, MCP-1, MCAF                                      Monocyte, immature DC and T cell chemotaxis, G-protein-coupled receptor signaling pathway, cell adhesion, JAK-STAT cascade, MAPK cascade, cellular calcium ion homeostasis, cellular response to IFN-γ, IL-1, and IL-6                                                                                                                                                                                                                                                                                                                                                                                                   Chemotaxis                                                   ([@B3])
  CCL3               CCL3, MIP-1α                                           Monocyte and T cell chemotaxis, G-protein-coupled receptor signaling pathway, cell adhesion, MAPK cascade, calcium-mediated signaling, cell activation, cellular response to IFN-γ, TNF-α, and IL-1, eosinophil degranulation, inflammatory response                                                                                                                                                                                                                                                                                                                                                                     Chemotaxis                                                   ([@B3])
  CCL4               CCL4, MIP-1β, LAG1                                     Monocyte and neutrophil and T cell chemotaxis, G-protein-coupled receptor signaling pathway, cell adhesion, calcium-mediated signaling, cell activation, cellular response to IFN-γ, TNF-α, and IL-1, inflammatory response, positive regulation of ERK1 and ERK2 cascade, positive regulation of GTPase activity                                                                                                                                                                                                                                                                                                        Chemotaxis                                                   ([@B3])
  CCL5               CCL5, RANTES                                           Monocyte, neutrophil and T cell chemotaxis, G-protein-coupled receptor signaling pathway, calcium-mediated signaling, cellular response to IFN-γ, TNF-α, and IL-1, inflammatory response                                                                                                                                                                                                                                                                                                                                                                                                                                 Chemotaxis                                                   ([@B3], [@B9])
  CCL8               CCL8, MCP-2, HC14                                      Monocyte, neutrophil and T cell chemotaxis, G-protein-coupled receptor signaling pathway, cellular response to IFN-γ, TNF-α, and IL-1, chronic inflammatory response, positive regulation of ERK1 and ERK2 cascade, positive regulation of GTPase activity, negative regulation of leukocyte proliferation                                                                                                                                                                                                                                                                                                               Chemotaxis                                                   ([@B3])
  CCL17              CCL17, TARC, ABCD-2                                    Monocyte and T cell chemotaxis, G-protein-coupled receptor signaling pathway, cellular response to IFN-γ, TNF-α, and IL-1, inflammatory response, positive regulation of ERK1 and ERK2 cascade, positive regulation of GTPase activity                                                                                                                                                                                                                                                                                                                                                                                   Chemotaxis/T cells                                           ([@B5])
  CCL18              CCL18, PARC, MIP-4, AMAC-1, DC-CK1                     Monocyte, neutrophil and T cell chemotaxis, G-protein-coupled receptor signaling pathway, cellular response to IFN-γ, TNF-α, and IL-1, inflammatory response, positive regulation of ERK1 and ERK2 cascade, positive regulation of GTPase activity                                                                                                                                                                                                                                                                                                                                                                       Chemotaxis                                                   ([@B3])
  CCL19              CCL19, MIP-3β, ELC                                     Mature DC and T cell chemotaxis, G-protein-coupled receptor signaling pathway, T cell costimulation, cell maturation, cellular response to IFN-γ, TNF-α, and IL-1, inflammatory response, activation of JUN kinase activity, establishment of T cell polarity, immunological synapse formation, inflammatory response, positive regulation of IL-1β, IL-12, and TNF-α secretion, positive regulation of ERK1 ERK2 JNK cascade, response to PGE                                                                                                                                                                           Chemotaxis, chemotaxis/T cells                               ([@B3], [@B5])
  CCL20              MIP-3α, LARC, Exodus                                   Immature DC monocyte neutrophil and T cell chemotaxis, G-protein-coupled receptor signaling pathway, cellular response to IL-1, TNF-α, and LPS, inflammatory response, positive regulation of ERK1 and ERK2 cascade                                                                                                                                                                                                                                                                                                                                                                                                      Th1/B cells                                                  ([@B19])
  CCL21              CCL21, SLC, 6Ckine, TCA4                               Mature DC neutrophil and T cell chemotaxis, G-protein-coupled receptor signaling pathway, T cell costimulation, cell maturation, cellular response to IFN-γ, TNF-α, and IL-1, inflammatory response, cell maturation, establishment of T cell polarity, negative regulation of DC dendrite assembly, positive regulation of DC APC function, immunological synapse formation, inflammatory response, activation of GTPase activity, cellular response to IL-1 and TNF-α, positive regulation of ERK1 ERK2 JNK cascade, response to PGE                                                                                   Chemotaxis, chemotaxis/T cells                               ([@B3], [@B5])
  CCL22              CCL22, MDC, ABCD-1, DC/B-CK                            Monocyte and T cell chemotaxis, G-protein-coupled receptor signaling pathway, cellular response to IFN-γ, TNF-α, and IL-1, inflammatory response, positive regulation of ERK1 and ERK2 cascade, positive regulation of GTPase activity                                                                                                                                                                                                                                                                                                                                                                                   Chemotaxis/T cells                                           ([@B5])
  CCR2               CCR2, CD192, CC-CKR2                                   Monocyte, immature DC and lymphocyte chemotaxis, G-protein-coupled receptor signaling pathway, positive regulation of inflammatory response, JAK--STAT cascade, negative regulation of eosinophil degranulation, positive regulation of Th1 immune response, negative regulation of Th2 immune response, positive regulation of IL-1β, IL-2, IL-6, and TNF production                                                                                                                                                                                                                                                    Chemotaxis/Th1/cytotoxicity/activation                       ([@B9])
  CCR4               CCR4, CD194, ChemR13, CC-CKR4                          Monocyte and lymphocyte chemotaxis, G-protein-coupled receptor signaling pathway, inflammatory response, tolerance induction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Chemotaxis/Th1/cytotoxicity/activation                       ([@B9])
  CCR5               CCR5, CD195                                            Myeloid and lymphocyte chemotaxis, G-protein-coupled receptor signaling pathway, inflammatory response, negative regulation of macrophage apoptotic process, positive regulation of IL-1, IL-6, and TNF production, co-receptor of HIV                                                                                                                                                                                                                                                                                                                                                                                   Chemotaxis/Th1/cytotoxicity/activation, Th1/B cells          ([@B9], [@B19])
  CCR7               CCR7, CD197, CMKBR7, CC-CKR7, BLR2, EBI1               Monocyte mature DC and lymphocyte chemotaxis, G-protein-coupled receptor signaling pathway, inflammatory response, positive regulation of ERK1 and ERK2 cascade, positive regulation of GTPase activity, establishment of T cell polarity, negative thymic T cell selection, positive regulation of JNK cascade, positive regulation of T cell costimulation and TCR signaling pathway, positive regulation of APC function, positive regulation of humoral immunity, regulation of IFN-γ, IL-1β, and IL-12 production                                                                                                   Chemotaxis/Th1/cytotoxicity/activation                       ([@B9])
  CD3e               CD3, TCRE, IMD18                                       T cell activation and costimulation, TCR signaling pathway, negative thymic T cell selection, positive regulation of T cell proliferation and anergy, positive regulation of IFN-γ, IL-2, and IL-4 production                                                                                                                                                                                                                                                                                                                                                                                                            Chemotaxis/T cells, chemotaxis/Th1/cytotoxicity/activation   ([@B5], [@B9])
  CD4                CD4                                                    T cell activation, T cell differentiation, T cell selection, cytokine production                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Chemotaxis/Th1/cytotoxicity/activation, Th1/B cells          ([@B9], [@B19])
  CD5                CD5, LEU1                                              T cell costimulation, apoptotic signaling pathway, cell proliferation, cell recognition, receptor-mediated endocytosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Th1/B cells                                                  ([@B19])
  CD8A               CD8A, Leu2, p32                                        T cell activation, T cell-mediated immunity, cell surface receptor signaling pathway, cytotoxic T cell differentiation, defense response to virus                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Chemotaxis/Th1/cytotoxicity/activation                       ([@B9])
  CD19               CD19, B4, CVID3                                        B-cell receptor signaling pathway, cell surface receptor signaling pathway, cellular defense response, phosphatidylinositol-mediated signaling, regulation of immune response                                                                                                                                                                                                                                                                                                                                                                                                                                            Chemotaxis/Th1/cytotoxicity/activation                       ([@B9])
  CD20               CD20, MS4A1, LEU-16                                    B-cell lineage, B-cell proliferation, humoral immune response                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Th1/B cells                                                  ([@B18], [@B19])
  CD28               CD28, Tp44                                             T cell costimulation, TCR signaling pathway, negative thymic T cell selection, positive regulation of T cell proliferation, positive regulation of IL-2, IL-4, and IL-10 production, immunological synapse, positive regulation of isotype switching to IgG, humoral immune response                                                                                                                                                                                                                                                                                                                                     Chemotaxis/Th1/cytotoxicity/activation                       ([@B9])
  CD38               CD38, ADPRC1                                           T cell activation, positive regulation of B-cell proliferation, B-cell receptor signaling pathway, negative regulation of apoptotic process, cell adhesion, calcium signaling, response to IL-1                                                                                                                                                                                                                                                                                                                                                                                                                          Chemotaxis/Th1/cytotoxicity/activation, Th1/B cells          ([@B9], [@B19])
  CD40               CD40, TNFRSF5                                          B-cell proliferation, inflammatory response, positive regulation of B-cell proliferation, positive regulation of MAP kinase activity, positive regulation of IL-12 production, positive regulation of isotype switching to IgG, regulation of Ig secretion, TNF-mediated signaling pathway                                                                                                                                                                                                                                                                                                                               Chemotaxis/Th1/cytotoxicity/activation, Th1/B cells          ([@B9], [@B19])
  CD40L              CD40 ligand, TRAP, CD154, HIGM1, TNFSF5, IGM           B-cell differentiation and proliferation, T cell costimulation, Ig secretion, isotype switching, negative regulation of apoptotic process, inflammatory response, positive regulation of NF-kappaB transcription factor activity, positive regulation of T cell proliferation, positive regulation of IL-4, IL-10, and IL-12 production, TNF-mediated signaling pathway                                                                                                                                                                                                                                                  Chemotaxis/Th1/cytotoxicity/activation                       ([@B9])
  CD62L              CD62L, L-selectin, LECAM1, LAM1                        Cell adhesion, leukocyte migration, regulation of immune response                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Chemotaxis/Th1/cytotoxicity/activation                       ([@B9])
  CD68               CD68, LAMP4, GP110, SCARD1                             Cellular response to organic substance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Chemotaxis/Th1/cytotoxicity/activation                       ([@B9])
  CD80               CD80, B7, BB1, B7-1, CD28LG1                           T cell activation, T cell costimulation, intracellular signal transduction, phosphatidylinositol-mediated signaling, positive regulation of Th1 cell differentiation, positive regulation of αβT cell proliferation, positive regulation of IL-2                                                                                                                                                                                                                                                                                                                                                                         Chemotaxis/Th1/cytotoxicity/activation                       ([@B9])
  CD86               CD86, B7-2, B70, CD28LG2                               B and T cell activation, T cell costimulation, cellular response to cytokine stimulus, DC activation, negative regulation of T cell anergy, phosphatidylinositol-mediated signaling, positive regulation of Th2 differentiation and T cell proliferation, positive regulation of IL-2 and IL-4 biosynthetic process, positive regulation of transcription and DNA-templated, response to IFN-γ, TLR3 signaling pathway                                                                                                                                                                                                   Chemotaxis/Th1/cytotoxicity/activation                       ([@B9])
  CD200              CD200, OX-2                                            Regulation of immune response, negative regulation of macrophage activation, cell recognition                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Tfh cells                                                    ([@B12])
  CSF2               CSF2, GM-CSF                                           DC differentiation, macrophage activation, MAPK cascade, negative regulation of cytolysis, positive regulation of cell proliferation, positive regulation of IL-23 production, positive regulation of gene expression                                                                                                                                                                                                                                                                                                                                                                                                    Th1/B cells                                                  ([@B19])
  CTLA-4             CTLA-4, CD152, IDDM12, ALPS5, GSE                      T cell costimulation, negative regulation of Treg differentiation, negative regulator of B-cell proliferation, B-cell receptor signaling pathway, positive regulation of apoptotic process                                                                                                                                                                                                                                                                                                                                                                                                                               Chemotaxis/Th1/cytotoxicity/activation                       ([@B9])
  CXCL9              CXCL9, MIG, CMK                                        Neutrophil and T cell chemotaxis, Th1 polarization, G-protein-coupled receptor signaling pathway, inflammatory response, regulation of cell proliferation                                                                                                                                                                                                                                                                                                                                                                                                                                                                Chemotaxis, Th1 orientation                                  ([@B3])
  CXCL10             CXCL10, IP10                                           Neutrophil monocyte and T cell chemotaxis, Th1 polarization, G-protein-coupled receptor signaling pathway, inflammatory response, positive regulation of cell proliferation                                                                                                                                                                                                                                                                                                                                                                                                                                              Chemotaxis, chemotaxis/Th1/cytotoxicity/activation           ([@B3], [@B9])
  CXCL11             CXCL11, IP9, I-TAC                                     T cell chemotaxis, Th1 polarization, G-protein-coupled receptor signaling pathway, inflammatory response, positive regulation of cell proliferation                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Chemotaxis, chemotaxis/Th1/cytotoxicity/activation           ([@B3], [@B9])
  CXCL13             CXCL13, BLC, BCA1, SCYB13                              B and Tfh cell chemotaxis, germinal center formation, lymph node development, regulation of humoral immunity, regulation of cell proliferation                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Chemotaxis, chemotaxis/T cells, Tfh cells                    ([@B3], [@B5], [@B12], [@B18], [@B19])
  CXCR3              CXCR3, CD182, CD183, GPR9                              Neutrophil and T cell chemotaxis, Th1 polarization, G-protein-coupled receptor signaling pathway, inflammatory response, apoptotic process, cell adhesion, calcium-mediated signaling                                                                                                                                                                                                                                                                                                                                                                                                                                    Chemotaxis/Th1/cytotoxicity/activation                       ([@B9])
  FasLG              Fas ligand, FASL, APTL, CD178, CD95L, TNFSF6, TNLG1A   T cell apoptotic process, activation of cysteine-type endopeptidase activity involved in apoptotic process, inflammatory cell apoptotic process, necroptotic signaling pathway, positive regulation of I-kappaB kinase/NK-kappaB signaling, positive regulation of cell proliferation, response to growth factor, transcription and DNA-templated                                                                                                                                                                                                                                                                        Chemotaxis/Th1/cytotoxicity/activation                       ([@B9])
  FBLN7              FBLN7, Fibulin-7, TM14                                 Cell adhesion                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Tfh cells                                                    ([@B12])
  GF11               GF11                                                   Regulation of transcription                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Th1/B cells                                                  ([@B19])
  GNLY               Granulysin, LAG2, NKG5                                 Cellular defense response, defense response to bacterium fungus, killing of cells of other organism                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Chemotaxis/Th1/cytotoxicity/activation                       ([@B9])
  HLA-DRA            HLA-DRA                                                T cell costimulation, TCR signaling pathway, antigen processing and presentation of exogenous peptide or polysaccharide antigen via MHC class II, IFN-γ-mediated signaling pathway, immune response                                                                                                                                                                                                                                                                                                                                                                                                                      Chemotaxis/Th1/cytotoxicity/activation                       ([@B9])
  ICAM-3             ICAM-3, CD50, ICAM-R                                   Cell adhesion, extracellular matrix organization, phagocytosis, regulation of immune response, stimulatory C-type lectin receptor signaling pathway                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Chemotaxis/T cells                                           ([@B5])
  ICOS               ICOS, CD278                                            T cell costimulation, T cell tolerance induction, immune response                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Chemotaxis/Th1/cytotoxicity/activation, Tfh cells            ([@B9], [@B12])
  IFN-γ              IFN-γ                                                  T cell receptor signaling pathway, Th1-related cytokine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Chemotaxis/Th1/cytotoxicity/activation                       ([@B9])
  IGSF6              IGSF6, DORA                                            Cell surface receptor signaling pathway, immune response                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Th1/B cells                                                  ([@B19])
  IL1R1              IL1RA, IL1R, CD121A                                    Cell surface receptor signaling pathway, IL-1-mediated signaling pathway, regulation of inflammatory response, response to TGF-β                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Th1/B cells                                                  ([@B19])
  IL1R2              IL1R2, CD121b, IL1RB                                   Inflammatory response, cytokine-mediated signaling pathway                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Th1/B cells                                                  ([@B19])
  IL-2               IL-2, lymphokine, TCGF                                 MAPK cascade, T cell differentiation, adaptive immune response, extrinsic apoptosis signaling pathway in absence of ligand, NK cell activation, negative regulation of B-cell apoptotic process, positive regulation of B and activated T cell proliferation, positive regulation of Ig secretion, positive regulation of IFN-γ and IL-17 production, positive regulation of isotype switching to IgG, positive regulation of Treg differentiation, regulation of T cell homeostatic proliferation                                                                                                                       Chemotaxis/Th1/cytotoxicity/activation                       ([@B9])
  IL2RA              IL2RA, CD25, IL2R, p55                                 Activation-induced cell death of T cells, positive regulation of activated T cell proliferation, positive regulation of T cell differentiation, inflammatory response, IL-2-mediated signaling pathway, regulation of T cell tolerance induction                                                                                                                                                                                                                                                                                                                                                                         Th1/B cells                                                  ([@B19])
  IL-10              IL-10, TGIF, GVHDS, CSIF                               B-cell differentiation, inflammatory response, negative regulation of T- and B-cell proliferation, negative regulation of apoptotic process, negative regulation of cytokine activity, negative regulation of IFN-γ, IL-1, IL-12, IL-18, IL-6, IL-8, and TNF production, negative regulation of myeloid DC activation, positive regulation of JAK-STAT cascade, regulation of isotype switching, Th3/Tr1/regulatory immune responses                                                                                                                                                                                     Chemotaxis/Th1/cytotoxicity/activation, Th1/B cells          ([@B9], [@B19])
  IL-12B             IL12B, CLMF, NKSF, IMD28, IMD29                        Positive regulation of Th1 and Th17 immune responses, Th differentiation, cellular response to IFN-γ, defense response to virus, positive regulation of NK and T cell activation, positive regulation of memory T cell differentiation, regulation of IL-10, IL-12, IL-17, TNF-α, and GM-CSF production, positive regulation of NK T cell activation and proliferation, positive regulation of T cell-mediated cytotoxicity, regulation of tyrosine phosphorylation of STAT1                                                                                                                                             Chemotaxis/Th1/cytotoxicity/activation                       ([@B9])
  IL-15              IL-15                                                  NK T cell proliferation, extra-thymic T cell selection, inflammatory response, LN development, positive regulation of NK and T cell proliferation, positive regulation of IL-17 production, signal transduction, tyrosine phosphorylation of STAT5                                                                                                                                                                                                                                                                                                                                                                       Chemotaxis/Th1/cytotoxicity/activation                       ([@B9])
  IL-16              IL-16, LCF, NIL16                                      Immune response, induction of positive chemotaxis, regulation of transcription and DNA-templated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Chemotaxis/T cells                                           ([@B5])
  IL-18              IL-18, IGIF, IL1γ, IL1F4                               MAPK cascade, Th1/Th2 immune response, GM-CSF biosynthetic process, inflammatory response, IFN-γ, IL-2, and IL-13 biosynthetic process, NK cell activation and proliferation, positive regulation of IL-17 and IFN-γ production, positive regulation of tyrosine phosphorylation of STAT3                                                                                                                                                                                                                                                                                                                                Chemotaxis/Th1/cytotoxicity/activation                       ([@B9])
  IRF4               IRF4, MUM1, LSIRF                                      T cell activation, Th17 cell lineage commitment, IFN-γ-mediated signaling pathway, positive regulation of IL-10, IL-13, IL-2, and IL-4 biosynthetic process, regulation of Th cell differentiation, Type-I IFN signaling pathway, positive regulation of transcription                                                                                                                                                                                                                                                                                                                                                   Th1/B cells                                                  ([@B19])
  ITGAL              ITGAL, CD11A, LFA-1                                    Extracellular matrix organization, T cell activation via TCR contact with antigen bound to MHC molecule on APC, leukocyte migration, heterotypic cell--cell adhesion, immune response, integrin-mediated signaling pathway, inflammatory response, phagocytosis, regulation of immune response                                                                                                                                                                                                                                                                                                                           Chemotaxis/T cells                                           ([@B5])
  ITGAD              ITGAD, ADB2, CD11D                                     Extracellular matrix organization, heterotypic cell--cell adhesion, immune response, integrin-mediated signaling pathway                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Chemotaxis/T cells                                           ([@B5])
  ITGA4              ITGA4, CD49D                                           B-cell differentiation, cell-matrix adhesion, diapedesis, extracellular matrix organization, heterotypic cell--cell adhesion, integrin-mediated signaling pathway, leukocyte migration tethering or rolling, regulation of immune response                                                                                                                                                                                                                                                                                                                                                                               Chemotaxis/T cells                                           ([@B5])
  LTA                LTA, Lymphotoxin α, TNFB, TNFSF1                       Positive regulation of apoptotic process, cell--cell signaling, positive regulation of humoral immune response mediated by circulating Ig, LN development, positive regulation of IFN-γ production, TNF-mediated signaling pathway                                                                                                                                                                                                                                                                                                                                                                                       Chemotaxis/Th1/cytotoxicity/activation                       ([@B9])
  MADCAM1            MADCAM1                                                Cell--matrix adhesion, extracellular matrix organization, heterotypic cell--cell adhesion, integrin-mediated signaling pathway, leukocyte tethering or rolling, receptor clustering, regulation of immune response, signal transduction                                                                                                                                                                                                                                                                                                                                                                                  Chemotaxis/T cells                                           ([@B5])
  PDCD1              PD-1                                                   T cell costimulation, humoral immune response, positive regulator of T cell apoptotic process                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Tfh cells                                                    ([@B12])
  PRF1               Perforin, PFP, FLH2, PFN1                              Apoptotic process, cellular defense response, cytolysis, defense response to tumor cell, immunological synapse formation, transmembrane transport                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Chemotaxis/Th1/cytotoxicity/activation                       ([@B9])
  SDC1               SDC, CD138, syndecan                                   Cell migration, inflammatory response, canonical Wnt signaling pathway                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Th1/B cells                                                  ([@B19])
  SGPP2              SGPP2, Spp2, SPPase2                                   Regulation of immune response, positive regulation of signal transduction, positive regulation of NK-mediated cytotoxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Tfh cells                                                    ([@B12])
  SH2D1A                                                                    Signal transduction of T- and B-cell activation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Tfh cells                                                    ([@B12])
  STAT5A             STAT5A, MGF                                            JAK--STAT cascade, peptidyl-tyrosine phosphorylation, regulator of transcription                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Th1/B cells                                                  ([@B19])
  TBX21              T-Bet, TBLYM                                           T cell differentiation, lymphocyte migration, positive regulation of transcription and DNA-templated, positive regulation of isotype switching to IgG                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Chemotaxis/Th1/cytotoxicity/activation                       ([@B9])
  TIGIT              TIGIT, VSTM3, VSIG9                                    T cell co-inhibitory receptor, negative regulation of IL-12 production, positive regulation of IL-10 production                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Tfh cells                                                    ([@B12])
  TNF-α              TNF-α, DIF, TNFSF2                                     I-kappaB kinase/NF-kappaB signaling, JNK cascade, MAPK cascade, activation of MAPK and MAPKKK activities, humoral immune response, inflammatory response, necroptotic signaling pathway, negative regulation of cytokine secretion, negative regulation of cytokine and chemokine production, negative regulation of transcription and DNA-templated, positive regulation of ERK1 and ERK2 cascade, positive regulation of I-kappaB kinase/NF-kappaB signaling, positive regulation of JUN and MAP kinase activity, positive regulation of apoptotic process, positive regulation of humoral response and Ig secretion   Chemotaxis/Th1/cytotoxicity/activation                       ([@B9])
  TRAF6              TRAF6, RNF85                                           FcE receptor signaling pathway, JNK cascade, MyD88-dependent TLR signaling pathway, MyD88-independent TLR signaling pathway, TCR signaling pathway, Th1 immune response, activation of MAPK activity, Ag processing and presentation of exogenous peptide Ag, myeloid DC differentiation, positive regulation of T cell activation proliferation and cytokine production, positive regulation of IL-12 production, response to IL-1, TLR signaling pathway                                                                                                                                                               Th1/B cells                                                  ([@B19])
  VCAM-1             VCAM-1, CD106                                          B-cell differentiation, acute inflammatory response, cell--matrix adhesion, cellular response to TNF-α and VEGF, IFN-γ-mediated signaling pathway, leukocyte tethering or rolling, positive regulation of T cell proliferation, regulation of immune response, response to hypoxia                                                                                                                                                                                                                                                                                                                                       Chemotaxis/T cells                                           ([@B5])

*Genes selectively overexpressed in tumors having high density of TLS in cancer patients*.

In this mini review, we summarize the available data in the literature regarding the prognostic value of TLS in human cancers, and discuss how these structures are controlled and could be manipulated in order to increase anti-tumor immune responses.

TLS and Prognosis in Cancers {#S2}
============================

In recent years, numerous publications have assessed the prognosis associated with the presence of TLS in different types of tumors. Several strategies for their quantification have been used. Historically, the first method to measure the densities of TLS was the quantification of mature DCs (DC-Lamp^+^) within CD3^+^ T cell aggregates ([@B1], [@B20]). Although relatively challenging due to the relative low number of DC-Lamp^+^ DCs in some tumors (as compared to other immune populations), our group has described it as the most accurate marker for quantifying TLS ([@B28], [@B29]). Up-to-date, eight publications have found a positive association between increased densities of DC-Lamp^+^ DCs and prognosis, in several types of tumors, including NSCLC ([@B1], [@B2], [@B9]), melanoma ([@B20]), renal cell carcinoma \[RCC ([@B24])\], breast ([@B11]), and colorectal cancer ([@B15]) (Table [1](#T1){ref-type="table"} and Figure [1](#F1){ref-type="fig"}).

![**Prognostic value of TLS-associated biomarkers in primary and metastatic cancers**. The number of publications studying the impact of mature DCs, TLS-related gene signatures, B-cell aggregates, T cell aggregates, or H&E with regard to prognosis in human cancers is represented (12 cancer types have been included). Blue, orange, and red circles represent an association with good, none, and poor prognosis, respectively. The diameter of the circles represents the total number of tumors (*n*) that have been analyzed on these studies.](fimmu-07-00407-g001){#F1}

The analysis of expression levels of TLS-related genes gives the possibility to rapidly assess the prognostic impact of these immune aggregates in large retrospective cohorts of tumors. So far, six studies have evaluated the prognostic impact of increased expression of TLS-related genes in cancer. Despite heterogeneity in the TLS-signatures, a significant correlation with good prognosis has been found in melanoma ([@B21]), colorectal ([@B3], [@B18]), and gastric ([@B19]) cancers (Table [1](#T1){ref-type="table"}). Interestingly, TLS found in inflammatory zones from hepatocellular carcinoma (HCC) correlate with increased risk for late recurrence and a trend toward decreased overall survival after HCC resection. This result could reflect an unexpected role for TLS, serving as niche for HCC progenitor cells *via* local production of Lymphotoxin (LT)-β ([@B25], [@B30]).

Another approach that has been used to estimate the densities of TLS in cancers is the quantification of B-cell aggregates by immunohistochemistry (IHC) (CD20^+^ B-cell aggregates or islets). The majority of publications measuring CD20^+^ aggregates (four out of five), accounting for more than 349 analyzed tumors, has determined that increased densities of this population correlate with good prognosis in several neoplasias, such as NSCLC ([@B2]), colorectal cancer liver metastasis ([@B27]), gastric ([@B19]), and oral ([@B22]) cancer (Table [1](#T1){ref-type="table"} and Figure [1](#F1){ref-type="fig"}). Most of the studies quantifying the CD3^+^ T cell aggregates and immune-cell aggregates (after hematoxylin counterstaining) have also found a positive impact on patient's prognosis. However, high numbers of B cell or T cell aggregates were found to have no impact on prognosis in biliary tract cancer and in stage III colorectal cancer, respectively. Further studies are needed to investigate whether it reflects that cell aggregates counting is not an accurate method to quantify TLS, or a functional impairment of TLS in these two cancer types (Table [1](#T1){ref-type="table"} and Figure [1](#F1){ref-type="fig"}).

Overall, despite the heterogeneity of methods used for quantifying TLS, most of the studies have consistently found a correlation between high densities of TLS and prolonged patient's survival in more than 10 different types of cancer (Table [1](#T1){ref-type="table"}). Further efforts should be made to optimize TLS-quantifying methods. Indeed the use of multicolor IHC will facilitate their characterization, by allowing the simultaneous detection of all major cell types and providing an extensive analysis of their cellular complexity.

TLS Neogenesis {#S3}
==============

The cellular composition and spatial organization of TLS share many similarities with those of SLO. Indeed, an increasing number of studies performed in a large variety of inflammatory disorders, in mice and in humans, suggest that their formation and regulation involve the same set of chemokines than those acting in lymphoid organogenesis.

Positive Regulators {#S3-1}
-------------------

Lymphotoxin, CCL21, and CXCL13 were shown to play a major role during TLS neogenesis, and are related to TLS presence in human tumors (Table [2](#T2){ref-type="table"}). In a mouse model of atherosclerosis, the activation of LTβR^+^ medial smooth muscle cells in the abdominal aorta by LT produced by CD11c^+^ CD68^+^ Ly6C^lo^ monocytes leads to the expression of CCL19, CCL21, CXCL13, and CXCL16 chemokines, which in turn trigger the recruitment of lymphocytes to the adventitia and the development of TLS ([@B31]). The same observation was made by Thaunat et al. in a rat model of chronic allograft rejection, in which M1-macrophages behaved as LTi cells in diseased arteries by expressing high levels of LTα and TNF-α ([@B32]). In human NSCLC, a TLS-related gene signature was identified, including CCL19, CCL21, IL-16, and CXCL13 ([@B5]) (Table [2](#T2){ref-type="table"}). Interestingly, Matsuda et al. recently suggested in a mouse intrapulmonary tracheal transplant model that lymphoid neogenesis was dependent on spleen tyrosine kinase (Syk)-signaling. Decreased expression of CXCL12, CXCL13, and VEGF-α, lower B-cell recruitment into allograft, and smaller lymphoid aggregate area were observed in Syk-deficient recipient mice as compared to controls ([@B33]).

The generation of HEVs is also a critical step in TLS neogenesis. HEV endothelial cells express LTβR, and the continuous engagement of LTβR on HEVs by LT^+^ CD11c^+^ DCs is critical for the induction and maintenance of the mature HEV phenotype required for the extravasation of blood lymphocyte into LNs ([@B34]--[@B37]). In addition, CD11c^+^ DCs can be sources of proangiogenic factors, such as VEGF, favoring the development of HEVs, and ultimately lymphocyte entry into LN ([@B38]--[@B41]). Consistently, LTβ expression correlates with that of HEV-associated chemokines in human breast cancer, and DC-Lamp^+^ DC density correlates with HEV density, lymphocyte infiltration, and favorable clinical outcome ([@B11]). Other cell types were shown to favor the development of HEV. For instance, ectopic expression of CCL21 in the thyroid gives rise first to the recruitment of CD3^+^ CD4^+^ T cells followed by DC, and this DC-T cross-talk is required for the local development of both TLS and mature HEV ([@B42]). Tumor-infiltrating CD8^+^ T cells and NK cells were also shown to drive the *de novo* development of PNAd^+^ TNFRI^+^ CCL21^+^ HEV-like blood vessels through the production of LT and IFN-γ ([@B43]).

Th17 cells share many developmental and effector markers with LTi cells, including the nuclear hormone receptor retinoic acid-related orphan receptor γt (RORγt), which promotes not only the production of IL-17 and IL-22 by Th17 cells, LTi cells, and other RORγt^+^ innate lymphoid cells (ILCs), but also cell membrane expression of LT \[reviewed in Ref. ([@B44])\]. In mice lungs, the formation of TLS \[called here induced-bronchus-associated lymphoid tissues (i-BALT)\] following LPS sensitization was dependent of IL-17 production by T cells, including Th17 and γδ T cells ([@B45]). This observation was also observed in a mouse experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis ([@B46]). Similarly, IL-17α-deficient mice exposed to cigarette smoke displayed decreased number of ectopic lymphoid follicles and decreased expression of CXCL12 as compared to wild-type mice in a model of chronic obstructive lung disease ([@B47]). It has also been suggested that Th17 cells, and IL-17 and IL-21 secretion by these cells can promote TLS neogenesis within human renal grafts, and are associated with the presence of active GC B cells and fast chronic rejection ([@B48]).

Other inflammatory cytokines also seem to promote TLS neogenesis. In rheumatoid arthritis (RA), high protein levels of IL-23 and IL-17F were detected in the synovial fluid of patients displaying ectopic lymphoid follicles, and a positive correlation was observed between CD21L mRNA (as a TLS marker) and IL-23 but also IL-17F, IL-21, and IL-22 mRNAs ([@B49]). IL-22 was also proposed to favor TLS induction ([@B50]). In a mouse model of virus-induced autoantibody formation in the salivary glands, it was shown that the ligation of IL-22R expressed by epithelial cells and fibroblasts leads to CXCL12 and CXCL13 production, allowing B-cell recruitment and TLS organization. In that case, IL-22 was mainly produced by γδ T cells and to a lesser extent by ILCs and NK cells during the early phase post-infection, and then by αβ T cells later after infection.

Negative Regulators {#S3-2}
-------------------

On the opposite, IL-27, a cytokine known to inhibit effector Th17 responses was recently suggested to negatively regulate the development of ectopic lymphoid-like structures in the synovial tissues of RA patients. While patients having a high density of TLS displayed high synovial levels of IL-17 and IL-21, high levels of IL-27 were observed in patients devoid of any TLS, and IL-27 expression was inversely correlated with CD3^+^ and CD20^+^ infiltrates and with synovitis. This observation was confirmed in a mouse model of RA ([@B51]).

Among the immune cells infiltrating tumors are regulatory T cells (Tregs), which have been considered in many reports as a marker of poor prognosis in cancer ([@B52], [@B53]). Tregs have been reported to negatively interfere with BALT development. Indeed in CCR7-deficient mice, BALTs developed spontaneously in the absence of infection, an event that is directly reverted by the adoptive transfer of wild-type Tregs but not CCR7^−/−^ Tregs ([@B54]). In human breast cancer, Tregs were detected in lymphoid aggregates surrounding tumor nests, and their presence was linked with the poor clinical outcome of patients ([@B55]). In mice bearing breast tumors, Treg depletion led to an increased density of HEV within the tumor, facilitated T cell recruitment from the blood, and ultimately induced tumor destruction ([@B56]). This observation is in accordance with a human study showing that HEV^high^ breast tumors correlated with a high LT-β expression, a high density of tumor-infiltrating mature DC, and a decreased FoxP3^+^/CD3^+^ T cell ratio ([@B11]).

More recently, a new mechanism involving regulation of TLS formation by Tregs was found, by dampening neutrophilic inflammation ([@B57]). The presence of neutrophils seemed to be critical for the neogenesis and the humoral immune function of i-BALT by enhancing B-cell activation and survival, Ig class switching to IgA as well as plasma cell survival ([@B57]).

Regulatory T cells have been shown to dampen the effector T cell response promoted within tumor-associated TLS. Treg depletion causes immune-mediated tumor destruction associated with an increased expression of co-stimulatory ligands by DCs and proliferation of T cells in a murine model of lung adenocarcinoma ([@B58]). Further studies should be carried out to analyze the prognostic importance of Tregs and their immunosuppressive potential in cancer patients according to their localization.

Altogether, TLS neogenesis and lymphoid organogenesis share many common mechanisms. On the one hand, the production of inflammatory cytokines (LT, IL-17, IL-22, and IL-23) and lymphoid chemokines (CCL21, CXCL12, and CXCL13), HEV development as well as the activation of DCs, B, and effector cells seem to be crucial events leading to TLS neogenesis under inflammatory conditions, such as cancers. On the other hand, the presence of Tregs appears to negatively impact TLS formation and TLS-associated T cell responses.

Manipulation of TLS for a Therapeutic Intervention in Cancer {#S4}
============================================================

A series of studies suggest that TLS are sites for generation and maintenance of adaptive anti-tumor responses ([@B10]). Therefore, TLS induction could be used as a therapeutic intervention for a better tumor control and prolonged survival of cancer patients. Since LN and TLS share many similarities in terms of cellular composition and organization, deciphering the mechanisms of lymphoid organogenesis enables to first highlight some putative key molecules that can support TLS neogenesis.

Targeting Molecules Involved in Lymphoid Organogenesis {#S4-1}
------------------------------------------------------

The key cross-talk between LTi cells and lymphoid tissue organizer cells (LTo cells that are cells of mesenchymal origin) occurring during LN development involves several molecules along with RANK and its ligand, which lead to LTβR signaling ([@B59]). Therefore, targeting RANK/LT pathway may modulate TLS development through the activation of LTo cells. Currently, antagonists of LTα (Pateclizumab NCT01225393), LTβR (Baminercept, NCT01552681) and RANK signaling (NCT01973569) are under investigation in several inflammatory situations. A special attention should be made in cancer setting where these antagonists might block TLS formation and, hence, reduce survival. The use of agonists might rather present a benefit to cancer patients but no drugs have been developed so far.

Activation of LTβR signaling pathway in LTo cells induces VCAM-1 and ICAM-1 upregulation, and ultimately leukocyte infiltration ([@B60]). Because both molecules are known to be induced by inflammation, an ICAM-1 antagonist called Alicaforsen has been tested in autoimmune diseases (NCT00048113, NCT00063830). We can speculate that the development of VCAM-1/ICAM-1 agonists would promote LTi-like cells-LTo clusterings and improve the leukocyte recruitment in order to generate cancer-associated TLS.

IL-7 receptor (CD127) signaling has been reported as a key pathway for TLS neogenesis ([@B61]). IL-7 is not only crucial for the survival and proliferation of LTi cells but also for GC formation and Tfh differentiation ([@B62]). To date, only one pharmacologic agent (IL-7R) is under investigation in NOD mice to deplete autoreactive T cells and to regulate pro-inflammatory mediators ([@B63]).

Altogether, as a counterpart of autoimmune diseases, development of agonist molecules targeting lymphoid organogenesis might be a promising strategy for the initiation and the maintenance of TLS in cancers.

Modulation of Chemokine and Cytokine Networks {#S4-2}
---------------------------------------------

Lymphoid chemokines represent a good therapeutic target for the modulation of TLS (Table [2](#T2){ref-type="table"}). The CCL19--CCL21/CCR7 and CXCL13/CXCR5 couples are induced after LT-βR signaling during lymphoid genesis ([@B60]). They are overexpressed in TLS of melanoma ([@B21]), colorectal ([@B3]), and lung ([@B5]) cancer patients. Using lymphoid chemokines or their agonists could be a promising strategy to induce TLS neogenesis in cancers. For example, CCL21 has been shown to attract circulating naïve T cells and DCs in tumors, and contribute to the control of tumor growth ([@B64]--[@B66]). A Phase I clinical trial is currently under investigation in NSCLC patients receiving intra-tumoral injections of CCL21-transduced autologous DCs (NCT00601094, NCT01574222). It is tempting to speculate that this vaccine therapy would boost TLS formation in tumors associated with an influx of lymphocytes, an effective anti-tumor immune response, and a reduction of tumor burden.

IL-21, which is mainly secreted by Th17 cells and neutrophils, represents also an interesting molecular target. First, this cytokine has been shown to promote TLS neogenesis in lungs after acute LPS exposure and IL-21^−/−^ mice exhibit fewer TLS in allografts than the control group ([@B57]). Second, IL-21 can enhance B and plasma cell survival as well as B-cell-dependent immunity, and induce conventional T cells to become refractory to Treg immunosuppression ([@B48], [@B57], [@B67]). Even if IL-21 can block IL-2 production with deleterious consequences in terms of Treg differentiation, IL-21 can substitute for IL-2 as a T cell growth factor ([@B68]). Recombinant IL-21 is currently tested in many clinical trials, alone or in combination with chemotherapy, therapeutic antibodies or tyrosine kinase inhibitors (e.g., NCT00617253, NCT00389285, NCT00095108, NCT01629758, NCT00336986, and NCT01489059). Altogether, it is likely that IL-21 could promote a robust anti-tumor immunity in a TLS-dependent manner.

Conclusion and Perspectives {#S5}
===========================

By facilitating the direct entry of CCR7^+^ naïve T cells and CXCR5^+^ B cells into tumors through HEVs, TLS allow T cells to differentiate into effector cells upon contact with mature DCs and B cells to form GC, protected from the immunosuppressive milieu of the tumor microenvironment. Therefore, TLS represent sites for the induction and maintenance of the local and systemic anti-tumor responses, which confer long-term protection against metastasis and, hence, correlate with good prognosis for the patients. Indeed, therapies aiming to increase TLS formation may allow generating anti-tumor responses directly *in situ* and would be beneficial in patients with high mutational load. TLS may also constitute biomarkers of anti-tumor response in patients undergoing immunotherapies. Thus, TLS induction was observed in cervical cancer patients vaccinated with HPV DNA ([@B69]) or with G-VAX ([@B70]), and one may speculate that TLS signature could be used to evidence response to therapies that unlock the adaptive immune responses.
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